Authors: Kateřina Kamaradová 1,2; Václav Stejskal 1; Dominika Écsiová 3 Authors place of work: Fingerlandův ústav patologie, Lékařská fakulta Univerzity Karlovy a Fakultní nemocnice Hradec Králové, Hradec Králové 1; Unilabs Pathology k. s., Laboratoř Praha, Praha 2; IV. interní hematologická klinika, Lékařská fakulta Univerzity Karlovy a Fakultní nemocnice Hradec Králové, Hradec Králové 3 Published in the journal: Čes.-slov. Patol., 62, 2026, No. 1, p. 17-34 Category: Přehledový článek
Castleman disease (CD) is a mesmerising group of disorders mainly affecting lymph nodes sharing some morphological features but with heterogeneous aetiology, clinical presentation and therapeutic approaches. Morphologically, hyaline-vascular (or hypervascular), plasmacytic, and mixed types of changes are distinguished. Confirmation of the diagnosis and subtype of Castleman disease involves meeting or excluding several clinical criteria and therefore requires close cooperation with a clinician. Unicentric Castleman disease involves usually a solitary enlarged lymph node with mild symptoms and excision surgery is often curative. Multicentric forms of Castleman disease affect multiple groups of lymph nodes and are associated with varying degrees of systemic clinical symptoms. Multicentric Castleman disease is either idiopathic or associated with human herpesvirus 8 infection or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes). Idiopathic multicentric Castleman disease is further divided into a variant associated with TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis / renal dysfunction, and organomegaly), idiopathic plasmacytic lymphadenopathy type, and not otherwise specified variant. The treatment of multicentric forms of Castleman disease is complex and depends on etiological factors, including biological therapy, chemotherapy, or interleukin-6 activity inhibition. The aim of this educational text is to present the current view of Castleman disease and provide a comprehensive description of the morphological changes and clinical characteristics of the individual subtypes of Castleman disease.
Castleman disease – POEMS syndrome – TAFRO syndrome – unicentric Castleman disease – idiopathic multicentric Castleman disease – HHV-8-positive multicentric Castleman disease – hyalinne-vascular morphology – hypervascular morphology – plasma cell type
1. Castleman B, Towne VW. Case records of the Massachusetts General Hospital: Case No. 40011. N Engl J Med 1954; 250(1): 26-29
2. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer 1956; 9 : 822–830.
3. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972; 29(3): 670 - 683.
4. Frizzera G, Banks PM, Massarelli G, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease. Pathological findings in 15 patients. Am J Surg Pathol 1983; 7 : 211–231.
5. Gaba AR, Stein RS, Sweet DL, et al. Multicentric giant lymph node hyperplasia. Am J Clin Pathol 1978; 69 : 86–90.
6. Frizzera G, Peterson BA, Bayrd ED, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985; 3 : 1202–1216.
7. Weisenburger DD, Nathwani BN, Winberg CD, et al. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 1985; 16 : 162–172.
8. Bardwick PA, Zvaifler NJ, Gill GN, et al. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine 1980; 59(4): 311-322.
9. Dispenzieri A. POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management. Am J Hematol 2021; 96(7): 872 - 888.
10. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL6/BSF-2) in Castleman‘s disease. Blood 1989; 74(4): 1360-1367.
11. Yoshizaki K, Murayama S, Ito H, et al. The Role of Interleukin-6 in Castleman Disease. Hematol Oncol Clin North Am 2018; 32(1): 23 - 36.
12. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994; 266 : 1865–1869.
13. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi’s sarcoma in patients with and without HIV infection. N Engl J Med 1995; 332 : 1181–1185.
14. Cesarman E, Chang Y, Moore PS, et al. Kaposi’s sarcoma associated herpesvirus-like DNA sequences in AIDS-related body-cavity - -based lymphomas. N Engl J Med 1995; 332 : 1186–1191.
15. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi’s sarcomaassociated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 1995; 86 : 1276–1280.
16. Dupin N, Gorin I, Deleuze J, et al. Herpes-like DNA sequences, AIDS-related tumors, and Castleman’s disease. N Engl J Med 1995; 333 : 798.
17. Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman‘s disease. Ann Oncol 2009; 20(4): 775-779.
18. Liu AaY, Nabel CS, Finkelman BS, et al. Idiopathic multicentric Castleman‘s disease: a systematic literature review. Lancet Haematol 2016; 3(4): e163-e175.
19. Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood 2020; 135(16): 1353-1364.
20. Carbone A, Borok M, Damania B, et al. Castleman disease. Nat Rev Dis Primers 2021; 7(1): 84.
21. Nishimura MF, Nishimura Y, Nishikori A, et al. Historical and pathological overview of Castleman disease. J Clin Exp Hematop 2022; 62(2): 60-72.
22. Hoffmann C, Oksenhendler E, Littler S, et al. The clinical picture of Castleman disease: a systematic review and meta-analysis. Blood Adv 2024; 8(18): 4924-4935.
23. Yu L, Tu M, Cortes J, et al. Clinical and pathological characteristics of HIV - and HHV - -8-negative Castleman disease. Blood 2017; 129(12): 1658-1668.
24. Takai K, Nikkuni K, Shibuya H et al. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Japanese J Clin Hematol 2010; 51 : 320-325.
25. Kawabata H, Takai K, Kojima M, et al. Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 2013; 53(1): 57-61.
26. Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV - -8-negative multicentric Castleman disease. Am J Hematol 2016; 91(2): 220-226.
27. Nishimura Y, Fajgenbaum DC, Pierson SK, et al. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol 2021; 96(10): 1241-1252.
28. Masaki Y, Kawabata H, Takai K, et al. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol 2020; 111(1): 155-158.
29. Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood 2014; 123(19): 2924-2933.
30. Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 2017; 129(12): 1646-1657.
31. Zhang L, Liu QH, Zhou H, et al. Asymptomatic multicentric Castleman disease: a potential early stage of idiopathic MCD. Blood Adv 2024; 8(21): 5598-5602.
32. Pierson SK, Brandstadter JD, Torigian DA, et al. Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry. Blood Adv 2025; 9(8): 1952-1965.
33. Chen LYC, Zhang L, Fajgenbaum DC. Expert Perspective: Diagnosis and Treatment of Castleman Disease. Arthritis Rheumatol. Published online June 2, 2025.
34. Gao YH, Liu YT, Zhang MY, et al. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. Br J Haematol 2024; 204(5): 1830-1837.
35. Mori S., Mohri N., Uchida T. et al. [Idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemia: a syndrome related to giant lymph node hyperplasia of plasma cell type]. J Jpn Soc Res 1980; 20(suppl): 55-65.
36. Kojima M, Nakamura N, Otuski Y, et al. Pulmonary lesion of idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemia appears to be a cause of lymphoplasmacytic proliferation of the lung: a report of five cases. Pathol Res Pract 2008; 204(3): 185-190.
37. Nishikori A, Nishimura MF, Nishimura Y, et al. Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease. Int J Mol Sci 2022; 23(18): 10301.
38. Nishikori A, Nishimura MF, Nishimura Y, et al. Distinct interleukin-6 production in IPL and TAFRO subtypes of idiopathic multicentric Castleman disease. Haematologica Published online September 11, 2025.
39. Judith AF, Naresh KN, Chadburn A et al. Tumour-like lesions with B-cell predominance – Castleman disease In: WHO Classification of Tumours Editorial Board. Haematolymphoid tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2024 [cited 2025/10/15]. (WHO classification of tumours series, 5th ed.; vol. 11). Available from: https://tumourclassification.iarc.who. int/chapters/XX.
40. Munshi N, Mehra M, van de Velde H et al. Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma 2015; 56(5): 1252-1260.
41. Mukherjee S, Martin R, Sande B et al. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy. Blood Adv 2022; 6(2): 359-367.
42. Lang E, van Rhee F. Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances. Blood Rev 2024; 64 : 101161.
43. Pelliccia S, Rogges E, Cardoni A, et al. The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman-like lymphadenopathies: A 20-year retrospective analysis of clinical and pathological features. Br J Haematol 2024; 204(2): 534-547.
44. Fajgenbaum DC, Shilling D. Castleman Disease Pathogenesis. Hematol Oncol Clin North Am 2018; 32(1): 11-21.
45. Vermi W, Lonardi S, Bosisio D, et al. Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma. J Pathol 2008; 216(3): 356-364.
46. Chang KC, Wang YC, Hung LY, et al. Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease. Mod Pathol 2014; 27(6): 823-831.
47. Li Z, Lan X, Li C, et al. Recurrent PDGFRB mutations in unicentric Castleman disease. Leukemia 2019; 33(4): 1035-1038.
48. Smith D, Eichinger A, Fennell É, et al. Spatial and single cell mapping of castleman disease reveals key stromal cell types and cytokine pathways. Nat Commun 2025; 16(1): 6009.
49. Horna P, King RL, Jevremovic D, et al. The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease. Haematologica 2023; 108(1): 207-218.
50. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 2000; 96(6): 2069-2073.
51. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000; 95(4): 1406-1412.
52. Chadburn A, Hyjek EM, Tam W, et al. Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)-infected B cells in HIV+ multicentric Castleman disease (MCD). Histopathology 2008; 53(5): 513-524.
53. Oksenhendler E, Boutboul D, Fajgenbaum D, et al. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol 2018; 180(2): 206-216.
54. Kanai K, Sawai S, Sogawa K, et al. Markedly upregulated serum interleukin-12 as a novel biomarker in POEMS syndrome. Neurology 2012; 79(6): 575-582.
55. Wang C, Huang XF, Cai QQ, et al. Remarkable expression of vascular endothelial growth factor in bone marrow plasma cells of patients with POEMS syndrome. Leuk Res 2016; 50 : 78-84.
56. Nagao Y, Mimura N, Takeda J, et al. Genetic and transcriptional landscape of plasma cells in POEMS syndrome. Leukemia 2019; 33(7): 1723-1735.
57. Miller I, Mumau MD, Shyamsundar S, et al. No evidence for active viral infection in unicentric and idiopathic multicentric Castleman disease by Viral-Track analysis. Sci Rep 2025; 15(1): 1676.
58. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med 2020; 383(23): 2255-2273.
59. Harada T, Kikushige Y, Miyamoto T, et al. Peripheral helper-T-cell-derived CXCL13 is a crucial pathogenic factor in idiopathic multicentric Castleman disease. Nat Commun 2023; 14(1): 6959.
60. van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 2018; 132(20): 2115-2124.
61. Alnoor F, Spies NC, Kumar J, et al. The Evolution and Recent Advances in Diagnostic Criteria for Idiopathic Multicentric Castleman Disease. Am J Hematol 2025; 100(11): 2064 - 2073.
62. Wing A, Xu J, Meng W, et al. Transcriptome and unique cytokine microenvironment of Castleman disease. Mod Pathol 2022; 35(4): 451-461.
63. Pierson SK, Shenoy S, Oromendia AB, et al. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Adv 2021; 5(17): 3445-3456.
64. Caballero JC, Conejero N, Solan L et al. Unraveling TAFRO Syndrome: An In-Depth Look at the Pathophysiology, Management, and Future Perspectives. Biomedicines 2024; 12(5): 1076.
65. Arenas DJ, Floess K, Kobrin D, et al. Increased mTOR activation in idiopathic multicentric Castleman disease. Blood 2020; 135(19): 1673-1684.
66. Sumiyoshi R, Koga T, Kawakami A. Biomarkers and Signaling Pathways Implicated in the Pathogenesis of Idiopathic Multicentric Castleman Disease/Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly (TAFRO) Syndrome. Biomedicines 2024; 12(6): 1141.
67. Milota T, Střížová Z, Sobotková M, Bartůňková J. Úloha interleukinu-6 v patogenezi a léčbě Castlemanovy choroby – pohled imunologa. Cas Lek Cesk 2023; 162(2-3): 106-111.
68. NCCN Clinical Practice Guidelines in Oncology – Castleman disease, verze 2.2025
69. DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 2009; 16(4): 236-246.
70. Medina EA, Fuehrer NE, FR et al. Dysplastic follicular dendritic cells in hyaline-vascular Castleman disease: a rare occurrence creating diagnostic difficulty. Pathol Int 2016; 66(9): 535-539.
71. Nishimura MF, Nishimura Y, Nishikori A, et al. Clinical and Pathological Characteristics of Hyaline-Vascular Type Unicentric Castleman Disease: A 20-Year Retrospective Analysis. Diagnostics (Basel) 2021; 11(11): 2008.
72. Alnoor F, Rangel A, Luo M, et al. Unicentric Castleman Disease: Updates and Novel Insights Into Spindle Cell Proliferations and Aggressive Forms of a Localized Disease. Int J Lab Hematol 2025; 47(1): 26-35.
73. Murro D, Agab M, Brickman A et al. Cytological features of Castleman disease: a review. J Am Soc Cytopathol 2016; 5(2): 100-106.
74. Ohgami RS, Zhao S, Ohgami JK, et al. TdT+ T-lymphoblastic populations are increased in Castleman disease, in Castleman disease in association with follicular dendritic cell tumors, and in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2012; 36(11): 1619 - 1628.
75. Saglam A, Singh K, Gollapudi S, et al. Indolent T-lymphoblastic proliferation: A systematic review of the literature analyzing the epidemiologic, clinical, and pathologic features of 45 cases. Int J Lab Hematol 2022; 44(4): 700-711.
76. Gasljevic G, Bonometti A, Anagnostopoulos I, et al. The morphological spectrum of Castleman disease and related disorders: a report from the Lymphoma Workshop of the 22nd Meeting of the European Association of Hematopathology. Virchows Arch 2025; 487(2): 253-273.
77. Rodriguez-Merino L, Montes-Moreno S. Castleman disease-type histopathological patterns of lymph nodes in patients with plasma cell neoplasia and POEMS syndrome. Ann Diagn Pathol 2025; 74 : 152414.
78. Zhou T, Wang HW, Pittaluga S et al. Multicentric Castleman disease and the evolution of the concept. Pathologica 2021; 113(5): 339 - 353.
79. Wu D, Lim MS, Jaffe ES. Pathology of Castleman Disease. Hematol Oncol Clin North Am 2018; 32(1): 37-52.
80. Zhang X, Niyazi S, Guo H et al. Mimickers and Associated Neoplasms of Castleman Disease. J Clin Transl Pathol 2025; 5(1): 20-29.
81. Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 2001; 97(7): 2130-2136.
82. Dargent JL, Lespagnard L, Sirtaine N et al. Plasmablastic microlymphoma occurring in human herpesvirus 8 (HHV-8)-positive multicentric Castleman‘s disease and featuring a follicular growth pattern. APMIS 2007; 115(7): 869-874.
83. van Rhee F, Oksenhendler E, Srkalovic G, et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv 2020; 4(23): 6039-6050.
84. Beckham TH, Yang JC, Chau KW et al. Excellent Outcomes with Surgery or Radiotherapy in the Management of Castleman Disease Including a Case of Oligocentric Disease. Clin Lymphoma Myeloma Leuk 2020; 20(10): 685 - 689.
85. Dao LN, Hanson CA, Dispenzieri A et al. Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients. Blood 2011; 117(24): 6438-6444.
86. Belyaeva E, Rubenstein A, Pierson SK, et al. Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review. Hematol Oncol 2022; 40(2): 191-201.
87. Nishikori A, Nishimura MF, Fajgenbaum DC, et al. Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease. J Clin Pathol 2025; 79(1): 43-49.
88. Fajgenbaum DC, Pierson SK, Kanhai K, et al. The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry. Br J Haematol 2022; 198(2): 307 - 316.
89. Han EJ, O JH, Jung SE, et al. PET/CT Findings of Castleman Disease Assessed by Histologic Subtypes and Compared with Laboratory Findings. Diagnostics (Basel) 2020; 10(12): 998.
90. Koa B, Borja AJ, Aly M, et al. Emerging role of 18F-FDG PET/CT in Castleman disease: a review. Insights Imaging 2021; 12(1): 35.
91. Koukalová R, Selingerová I, Řehák Z et al. FDG-PET/ CT v diagnostice a hodnocení léčebné odpovědi Castlemanovy choroby - retrospektivní studie 29 případů z jednoho centra. Klin Onkol 2021; 34(2): 120-127.
92. Blommers M, Selegean S, Wood RK, et al. Idiopathic multicentric Castleman disease with marrow fibrosis and extramedullary hematopoiesis. Eur J Haematol 2024; 113(6): 833-841.
93. Siddiqi IN, Brynes RK, Wang E. B-cell lymphoma with hyaline vascular Castleman disease-like features: a clinicopathologic study. Am J Clin Pathol 2011; 135(6): 901-914.
94. https://www.castlemandiseaseeducation. com/grading 2025_11_05 12 : 58
95. Nishimura MF, Haratake T, Nishimura Y, et al. International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis. Am J Hematol 2025; 100(9): 1502-1512.
96. Lyapichev KA, You MJ, Vega F et al. Classic Hodgkin lymphoma and Castleman disease: an entity appears to be emerging. Virchows Arch 2020; 477(3): 437-444.
97. Hsi ED, Lorsbach RB, Fend F, Dogan A. Plasmablastic lymphoma and related disorders. Am J Clin Pathol 2011; 136(2): 183-194.
98. Facchetti F, Simbeni M, Lorenzi L. Follicular dendritic cell sarcoma. Pathologica 2021; 113(5): 316-329.
99. Andriko JW, Kaldjian EP, Tsokos M et al. Reticulum cell neoplasms of lymph nodes: a clinicopathologic study of 11 cases with recognition of a new subtype derived from fibroblastic reticular cells. Am J Surg Pathol 1998; 22(9): 1048-1058.
100. Yagi H, Satou A, Enomoto Y, et al. ALK-Rearranged Mesenchymal Neoplasm With Hyaline-Vascular Castleman Disease-Like Features: A Case Report. Pathol Int 2025; 75(10): 538-543.
101. Naresh KN, Rice AJ, Bower M. Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma. Am J Surg Pathol 2008; 32(7): 1006-1012.
102. Sato Y, Kojima M, Takata K, et al. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman‘s disease. Mod Pathol 2009; 22(4): 589-599.
103. Cheuk W, Bledsoe JR. IgG4-related lymphadenopathy. Semin Diagn Pathol 2024; 41(2): 108-115.
104. Jo JH, Park YS, Jeon YK et al. Comparison of plasma cell type of Castleman‘s disease and IgG4-related sclerosing disease: a histopathological and immunohistochemical study. Pathobiology 2011; 78(4): 227-232.
105. Umehara H, Okazaki K, Kawa S, et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 2021; 31(3): 529-533.
106. Nishikori A, Nishimura MF, Nishimura Y, et al. Investigation of IgG4-positive cells in idiopathic multicentric Castleman disease and validation of the 2020 exclusion criteria for IgG4-related disease. Pathol Int 2022; 72(1): 43-52.
107. Bledsoe JR, Ferry JA, Neyaz A, et al. IgG4-related Lymphadenopathy: A Comparative Study of 41 Cases Reveals Distinctive Histopathologic Features. Am J Surg Pathol 2021; 45(2): 178-192.
108. Sasaki T, Akiyama M, Kaneko Y, et al. Distinct features distinguishing IgG4-related disease from multicentric Castleman‘s disease. RMD Open 2017; 3(1): e000432.
109. Nijim S, Fajgenbaum DC. Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy. Hematology Am Soc Hematol Educ Program 2024; 2024(1): 582-593.
110. Manabe A, Igawa T, Takeuchi M et al. Immunohistochemical analysis of IgA expression differentiates IgG4-related disease from plasma cell-type Castleman disease. Med Mol Morphol 2017; 50(1): 34-41.
111. Otani K, Inoue D, Fujikura K, et al. Idiopathic multicentric Castleman‘s disease: a clinicopathologic study in comparison with IgG4-related disease. Oncotarget 2018; 9(6): 6691-6706.
112. Han Y, Igawa T, Ogino K, et al. Hemosiderin deposition in lymph nodes of patients with plasma cell-type Castleman disease. J Clin Exp Hematop 2020; 60(1): 1-6.
113. González García A, Fernández-Martín J, Robles Marhuenda Á. Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis. Rheumatology (Oxford) 2023; 62(4): 1426-1435.
114. Pina-Oviedo S, Wang W, Vicknair E et al. Follicular lymphoma with hyaline-vascular Castleman disease-like follicles and CD20 positive follicular dendritic cells. Pathology 2017; 49(5): 544-547.
115. Dobrea C, Mihai M, Dănăilă E et al. „In situ“ mantle cell lymphoma associated with hyaline-vascular Castleman disease. Rom J Morphol Embryol 2011; 52(3 Suppl): 1147-1151.
116. Igawa T, Omote R, Sato H, et al. A possible new morphological variant of mantle cell lymphoma with plasma-cell type Castleman disease-like features. Pathol Res Pract 2017; 213(11): 1378-1383.
117. Du MQ, Diss TC, Liu H, et al. KSHV - and EBV - -associated germinotropic lymphoproliferative disorder. Blood 2002; 100(9): 3415-3418.
118. Peker D, Alkan S, Zhang L et al. HIV-associated plasmablastic multicentric Castleman disease with microlymphoma coinfected with HHV8 and EBV. J Hematopathol 2013; 6, 109–114.
119. Bhavsar T, Lee JC, Perner Y, et al. KSHV-associated and EBV-associated Germinotropic Lymphoproliferative Disorder: New Findings and Review of the Literature. Am J Surg Pathol 2017; 41(6): 795-800.
120. Gonzalez-Farre B, Martinez D, Lopez-Guerra M, et al. HHV8-related lymphoid proliferations: a broad spectrum of lesions from reactive lymphoid hyperplasia to overt lymphoma. Mod Pathol 2017; 30(5): 745-760.
121. Zanelli M, Zizzo M, Bisagni A, et al. Germinotropic lymphoproliferative disorder: a systematic review. Ann Hematol 2020; 99(10): 2243-2253.
122. Boutboul D, Fadlallah J, Chawki S, et al. Treatment and outcome of Unicentric Castleman Disease: a retrospective analysis of 71 cases. Br J Haematol 2019; 186(2): 269-273.
123. Lurain K, Yarchoan R, Uldrick TS. Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease. Hematol Oncol Clin North Am 2018; 32(1): 75-88.
124. van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman‘s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2014; 15(9): 966-974.
125. Deisseroth A, Ko CW, Nie L, et al. FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. Clin Cancer Res 2015; 21(5): 950-954.
126. Adam Z, Zeman D, Chodacki A, et al. Léčba Castlemanovy choroby siltuximabem – popis případu a přehled literatury. Klin Onkol 2023; 36(4): 320-329.
127. Lomas OC, Streetly M, Pratt G, et al. The management of Castleman disease. Br J Haematol 2021; 195(3): 328-337.
128. Ramaswami R, Lurain K, Polizzotto MN, et al. Characteristics and outcomes of KSHV - -associated multicentric Castleman disease with or without other KSHV diseases. Blood Adv 2021; 5(6): 1660-1670.
129. Bustamante MS, Pierson SK, Ren Y, et al. Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease. Haematologica 2024; 109(7): 2196-2206.
130. Pierson SK, Katz L, Williams R, et al. CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease. Nat Commun 2022; 13(1): 7236.
Zvyšte si kvalifikaci online z pohodlí domova
Nemáte účet? Registrujte se
Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.
